These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 10450674

  • 1. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M, Ajzenberg C, Benelhadj S, Lajeunie E, Lormeau B, Guillausseau PJ, Rohmer V, Vilain D, Mundler O, Warnet A.
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [Abstract] [Full Text] [Related]

  • 2. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 3. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 4. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ.
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, Warnet A.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [Abstract] [Full Text] [Related]

  • 6. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N, Furno A, Sforza A, Chiarini V, Graziano E, Zampa G, Turba E.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [Abstract] [Full Text] [Related]

  • 7. 111In-octreotide scintigraphy in pituitary adenomas.
    Tofani A, Cucchi R, Pompili A, Carapella C, Crecco M, Mottolese M, Maini CL.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
    [Abstract] [Full Text] [Related]

  • 8. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
    Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, Attanasio R, Milella M, Banfi G, Possa M.
    J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
    [Abstract] [Full Text] [Related]

  • 9. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
    Tumiati MN, Facchi E, Gatti C, Bossi A, Longari V.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
    [Abstract] [Full Text] [Related]

  • 10. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
    Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.
    Duet M, Mundler O, Ajzenberg C, Berolatti B, Chedin P, Duranteau L, Warnet A.
    Eur J Nucl Med; 1994 Jul; 21(7):647-50. PubMed ID: 7957351
    [Abstract] [Full Text] [Related]

  • 12. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 13. [Somatostatin analogs in the clinical management of pituitary neoplasms].
    Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S.
    Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
    [Abstract] [Full Text] [Related]

  • 14. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
    Acosta-Gómez MJ, Muros MA, Llamas-Elvira JM, Ramírez A, Ortega S, Sabatel G, Ramos C, de la Riva-Aguilar A.
    Br J Radiol; 2005 Feb; 78(926):110-5. PubMed ID: 15681321
    [Abstract] [Full Text] [Related]

  • 15. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.
    Lamberts SW, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi JC, Krenning EP.
    Front Neuroendocrinol; 1993 Jan; 14(1):27-55. PubMed ID: 8097480
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
    Rieger A, Rainov NG, Elfrich C, Klaua M, Meyer H, Lautenschläger C, Burkert W, Mende T.
    Neurosurg Rev; 1997 Jan; 20(1):7-12. PubMed ID: 9085281
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
    Meyer P, Bohnen NI, Barkan AL, Shapiro B.
    Nuklearmedizin; 1999 Jan; 38(2):66-7. PubMed ID: 10100234
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 19. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
    Podoba J, Hnilica P, Makaiová I, Kovácová S, Rybár M, Gecík K, Belan V, Steno J.
    Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
    [Abstract] [Full Text] [Related]

  • 20. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.